To animate the Banner

Talent Recruitment

Sales Department

Apply for post

Recruitment Position

Place of work

Number of Recruits

Salary Treatment

Obutiinib 1

Obitinib (trade name: Yinokai) is a highly selective new BTK inhibitor independently developed by Nuo Cheng Jianhua. Obitinib has an innovative compound structure, resulting in high selectivity, reduced off-target effects, and better efficacy and safety. Obitinib was approved for the treatment of relapsed/refractory marginal zone lymphoma (MZL) in China in April 2023 and was included in the national health insurance at the end of that year, becoming the first and only BTK inhibitor approved for the treatment of marginal zone lymphoma in China. The Company is initiating a Phase III confirmatory clinical trial of Obitinib against MZL. The clinical study of orbitinib in relapsed/refractory MZL showed an overall response rate (ORR) of 58.9 percent as assessed by the Independent Review Committee (IRC), and tumor shrinkage was observed in 92.2 percent of patients. More data can be found in the American Journal of Hematology (American Journal Of Hematology). Obitinib has been included in the "Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines 2024" and is listed as a level I recommend regimen for second-line treatment of marginal zone lymphoma.

Job Application

Name

Gender

Male

Female

Ethnic

Age

E-mail

Marriage

Unmarried

Married

Weight

Height

Native Place

political outlook

Expected location

education level

Professional

foreign language level

graduation school

Graduation time

—

Other Intended Positions

Contact Phone

Resume Upload

Please upload a resume file smaller than 5M ~

Self-evaluation

Security Verification

Job Application

Focus on us

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Contact Information

020-32030745

Monday to Friday 9:00~17:00

Virotech@virot.cn

Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City

粤ICP备XXXXXXXX号

Tags | city substation | Business License | Powered by www.300.cn